Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.31 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5876606 | 0.97 | KMT2A (0.34) | KMT2AMEN1LMNAL3MBTL1USP2 | |
| SCHEMBL5876201 | 0.92 | USP2 (0.34) | KMT2AMEN1LMNAL3MBTL1USP2 | |
| SCHEMBL5876198 | 0.92 | USP2 (0.37) | KMT2AMEN1LMNAUSP2MAPK1 | |
| SCHEMBL5876321 | 0.91 | KMT2A (0.34) | KMT2AMEN1LMNAL3MBTL1USP2 | |
| SCHEMBL5876550 | 0.89 | KMT2A (0.35) | KMT2AMEN1L3MBTL1USP2MAPK1 | |
| SCHEMBL5876984 | 0.89 | GPR6 (0.35) | KMT2AMEN1LMNAUSP2MAPK1 | |
| SCHEMBL5876672 | 0.89 | KMT2A (0.35) | KMT2AMEN1LMNAL3MBTL1MAPT | |
| SCHEMBL5876012 | 0.88 | NR1H2 (0.36) | KMT2AMEN1USP2MAPK1NOD2 | |
| SCHEMBL5877322 | 0.88 | GPR6 (0.36) | KMT2AMEN1L3MBTL1USP2MAPK1 | |
| SCHEMBL5876674 | 0.88 | USP2 (0.35) | KMT2AMEN1USP2MAPK1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119115-B2 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | AVENTIS PHARMA S.A. (FR) | 2006-10-10 | — | — | US | disclosed |
| US-20040162276-A1 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | AVENTIS PHARMA S.A. (FR) | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162276-A1 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | IDO1, IDO2, INMT | KMT2A 2326/4885MEN1 548/4885LMNA 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.